Market Place
Sourcing Support
Tyra Biosciences Reports Q3 2024 Financial Results & Highlights
07 Nov 2024 //
PR NEWSWIRE
Tyra Biosciences Gets IND Clearance for Pediatric BEACH301 Study
28 Oct 2024 //
PR NEWSWIRE
Tyra Bio Reports Data For TYRA-300 In Metastatic Urothelial Cancer
24 Oct 2024 //
PR NEWSWIRE
Tyra Biosciences To Host Call On Interim Data Of TYRA-300 On Oct 25
23 Oct 2024 //
PR NEWSWIRE
Tyra Present on TYRA-300 at 36th EORTC-AACR Symposium
11 Oct 2024 //
PR NEWSWIRE
Tyra Biosciences Appoints Doug, M.D., As Chief Medical Officer
10 Sep 2024 //
PR NEWSWIRE
Tyra Biosciences Reports Second Quarter 2024 Financial Results and Highlights
07 Aug 2024 //
PR NEWSWIRE
Tyra Biosciences Announces Preclinical Results For TYRA-300 In HCH
02 Jul 2024 //
PR NEWSWIRE
Tyra Biosciences Reports First Quarter 2024 Financial Results and Highlights
09 May 2024 //
PR NEWSWIRE
Tyra Biosciences Reports4Q FYR 2023 & Highlights
19 Mar 2024 //
PR NEWSWIRE
Tyra Biosciences to Present at Upcoming Investor Conferences
27 Feb 2024 //
PR NEWSWIRE
Tyra Bio to Present at Oppenheimer`s 34th Annual Life Sciences Conference
07 Feb 2024 //
PRESS RELEASE
Tyra Biosciences, Inc. Announces $200 Million Private Placement Financing
02 Feb 2024 //
PRESS RELEASE
Tyra Biosciences Receives FDA Rare Pediatric Disease Designation for TYRA-300
01 Feb 2024 //
PR NEWSWIRE
Tyra Biosciences Doses First Patient with TYRA-200
22 Dec 2023 //
PR NEWSWIRE
Tyra Biosciences Reports Third Quarter 2023 Financial Results and Highlights
07 Nov 2023 //
PR NEWSWIRE
Tyra Biosciences Announces Oral Presentations on TYRA-300 for Achondroplasia
21 Sep 2023 //
PR NEWSWIRE
Tyra Biosciences Reports Second Quarter 2023 Financial Results and Highlights
10 Aug 2023 //
PR NEWSWIRE
CEO Todd Harris Sells 75,810 Shares of Tyra Biosciences Inc (TYRA)
22 Jun 2023 //
GURUFOCUS
Tyra Biosciences Reports First Quarter 2023 Financial Results and Highlights
04 May 2023 //
PR NEWSWIRE
Tyra Biosciences to Participate in Upcoming Investor Conferences
29 Mar 2023 //
PR NEWSWIRE
Tyra Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights
22 Mar 2023 //
PR NEWSWIRE
Tyra Biosciences Expands Development of TYRA-300
01 Mar 2023 //
PR NEWSWIRE
Tyra Biosciences to Present at Upcoming Investor Conferences
22 Feb 2023 //
PRESS RELEASE
Oppenheimer Starts Tyra Biosciences (TYRA) at Outperform
02 Feb 2023 //
STREETINSIDER
Tyra Initiates SURF301 Phase 1/2 Study and Doses First Patient with TYRA-300
29 Nov 2022 //
PRNEWSWIRE
Tyra Biosciences Announces Planned CFO Transition
02 Nov 2022 //
BIOSPACE
Tyra Biosciences to Present Preclinical Data on TYRA-300 at ESMO 2022 Congress
05 Sep 2022 //
PRNEWSWIRE
Tyra Biosciences Reports Second Quarter 2022 Financial Results and Highlights
04 Aug 2022 //
PRESS RELEASE
Tyra Biosciences Reports First Quarter 2022 Financial Results and Highlights
05 May 2022 //
PRESS RELEASE
Tyra Bio Reports Q4 and Full Year 2021 Financial Results and Highlights
03 Mar 2022 //
PRNEWSWIRE
Three more biotechs hit Nasdaq as the sector
15 Sep 2021 //
ENDPTS
Tyra Biosciences soars over 50% on public debut
15 Sep 2021 //
SEEKINGALPHA
Tyra banks $173M to bring cancer resistance programs into clinic
15 Sep 2021 //
FIERCEBIOTECH
Tyra Biosciences upsizes IPO to 9 million shares vs. prior 6.7 million
14 Sep 2021 //
MARKETWATCH
Oncology biotech Tyra Biosciences sets terms for $101 million IPO
09 Sep 2021 //
RENAISSANCE CAPITAL
Tyra Biosciences wants to bank $100M for an IPO
23 Aug 2021 //
FIERCEBIOTECH
RA Capital to take preclinical biotech to Nasdaq as Tyra files S-1
23 Aug 2021 //
ENDPTS
Tyra banks $106M, adds to C-suite as it aims for clinic in 2022
31 Mar 2021 //
FIERCEBIOTECH
